This course has expired. You can still review the content but course credit is no longer available.
Geographic atrophy (GA) is an advanced form of age-related macular degeneration for which there is currently no treatment approved by the US FDA. This webinar will review in-depth the latest information on GA, including the investigative therapies showing positive outcomes in clinical trials. The expert faculty will also share their expertise related to the optimal imaging modalities for evaluating GA and share case studies for discussion.
Supported from an Educational Grant from Apellis.
Provided by Evolve Medical Education
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Evolve designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS
Recommended internet speed 5Mbps+
Rishi P. Singh, MD
Cole Eye Institute
Associate Professor of Ophthalmology
Lerner College of Medicine
Nathan Steinle, MD
California Retina Consultants
Santa Barbara, CA
Charles C. Wykoff, MD, PhD
Retina Consultants of Houston
Houston Methodist Hospital
Blanton Eye Institute
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Rishi P. Singh, MD, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Bausch + Lomb, Genentech, Novartis, and Regeneron Pharmaceuticals. Grant/Research Support: Apellis and Graybug.
Nathan Steinle, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Genentech, Novartis and Regeneron Pharmaceuticals; Grant Research Support: Genentech, Novartis and Regeneron Pharmaceuticals; Speaker: Genentech, Novartis and Regeneron Pharmaceuticals.
Charles C. Wykoff, MD, PhD, FACS, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera, Allergan, Genentech, Novartis, and Regeneron. Grant/Research Support: Allergan, Genentech, Novartis, and Regeneron. Speaker’s Bureau: Regeneron.
The Evolve staff and planners have no financial relationships with commercial interests.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Apellis.